S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(2.10%) $83.06
Gas
(2.10%) $1.754
Gold
(1.32%) $2 242.00
Silver
(1.18%) $25.04
Platinum
(1.37%) $922.20
USD/EUR
(0.39%) $0.927
USD/NOK
(0.87%) $10.86
USD/GBP
(0.12%) $0.792
USD/RUB
(0.13%) $92.56

Realtime updates for Enzo Biochem Inc [ENZ]

Exchange: NYSE Sector: Healthcare Industry: Diagnostics & Research
Last Updated28 Mar 2024 @ 16:00

0.00% $ 1.270

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...

Stats
Today's Volume 45 471.00
Average Volume 97 350.00
Market Cap 65.06M
EPS $0 ( 2024-03-19 )
Next earnings date ( $0 ) 2024-06-12
Last Dividend $0.0470 ( 1995-06-29 )
Next Dividend $0 ( N/A )
P/E -2.70
ATR14 $0.00500 (0.39%)
Insider Trading
Date Person Action Amount type
2024-02-23 Cannon Kara Buy 150 000 Common Stock
2024-02-21 Cannon Kara Buy 10 640 Common Stock
2024-02-21 Cannon Kara Sell 5 823 Common Stock
2024-02-23 Eckert Patricia Buy 75 000 Stock Option (to acquire shares of Common Stock)
2024-01-31 Pully Steven J Buy 79 365 Common Stock
INSIDER POWER
88.95
Last 85 transactions
Buy: 4 325 861 | Sell: 177 248

Volume Correlation

Long: 0.03 (neutral)
Short: -0.06 (neutral)
Signal:(47.86) Neutral

Enzo Biochem Inc Correlation

10 Most Positive Correlations
YSAC0.906
TSQ0.849
HZN0.841
DTC0.828
CRD-A0.819
10 Most Negative Correlations
FPEI-0.872
ASB-PE-0.868
CUBB-0.868
GL-0.855
FLR-0.852
NX-0.843
MBI-0.836
PQDI-0.832
BGSF-0.832
SPNT-PB-0.825

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enzo Biochem Inc Correlation - Currency/Commodity

The country flag 0.29
( neutral )
The country flag -0.27
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.70
( moderate )

Enzo Biochem Inc Financials

Annual 2023
Revenue: $31.06M
Gross Profit: $11.57M (37.24 %)
EPS: $-0.760
Q4 2023
Revenue: $-19.66M
Gross Profit: $-24.72M (125.76 %)
EPS: $0.250
Q3 2023
Revenue: $16.11M
Gross Profit: $1.64M (10.17 %)
EPS: $-0.300
Q2 2023
Revenue: $16.34M
Gross Profit: $1.26M (7.71 %)
EPS: $-0.220

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.340 - No dividend growth expected in the near future
Information
First Dividend $0.0470 1995-06-29
Last Dividend $0.0470 1995-06-29
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.0470 --
Avg. Dividend % Per Year 0.00% --
Score 0.81 --
Div. Sustainability Score 5.02
Div.Growth Potential Score 0.340
Div. Directional Score 2.68 --
Next Divdend (Est)
(2024-03-28)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.81
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
1995 $0.0470 0.58%
1996 $0 0.00%
1997 $0 0.00%
1998 $0 0.00%
1999 $0 0.00%
2000 $0 0.00%
2001 $0 0.00%
2002 $0 0.00%
2003 $0 0.00%
2004 $0 0.00%
2005 $0 0.00%
2006 $0 0.00%
2007 $0 0.00%
2008 $0 0.00%
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
NCZ Dividend Royal 2024-02-09 Monthly 22 7.79% 8.50
PDI Dividend Royal 2023-11-10 Monthly 13 7.86% 8.50
VGI Dividend Royal 2024-02-09 Monthly 13 7.36% 8.50
ORC Dividend Royal 2023-11-29 Monthly 12 9.23% 8.50
SRV Dividend Royal 2023-12-04 Monthly 18 7.53% 8.50
SBR Dividend Royal 2023-11-14 Monthly 38 7.74% 8.50
ZTR Dividend King 2024-02-09 Monthly 37 8.35% 8.50
MTR Dividend Royal 2023-10-30 Monthly 39 10.10% 8.50
GOF Dividend Royal 2023-11-14 Monthly 18 8.03% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM2.581.50010.0010.00[0 - 0.5]
returnOnAssetsTTM0.3331.20010.0010.00[0 - 0.3]
returnOnEquityTTM0.5451.5005.067.59[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.200.80010.008.00[1 - 3]
quickRatioTTM2.780.80010.008.00[0.8 - 2.5]
cashRatioTTM2.581.50010.0010.00[0.2 - 2]
debtRatioTTM0.0444-1.5009.26-10.00[0 - 0.6]
interestCoverageTTM33.771.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
freeCashFlowPerShareTTM-0.9092.00-0.455-0.909[0 - 20]
debtEquityRatioTTM0.0621-1.5009.75-10.00[0 - 2.5]
grossProfitMarginTTM-1.2031.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3481.000-8.96-8.96[0.1 - 0.6]
cashFlowToDebtRatioTTM-10.101.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.1290.800-2.47-1.977[0.5 - 2]
Total Score5.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM1.9421.0009.900[1 - 100]
returnOnEquityTTM0.5452.506.827.59[0.1 - 1.5]
freeCashFlowPerShareTTM-0.9092.00-0.303-0.909[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.03151.500-3.540[0.5 - 2]
operatingCashFlowSalesRatioTTM-3.471.000-10.000[0.1 - 0.5]
Total Score0.340

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators